Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (DE:JNJ)
XETRA:JNJ
Holding DE:JNJ?
Track your performance easily
JNJ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.78 - €154.00
Previous Close€147.48
Volume8.00
Average Volume (3M)2.45K
Market Cap
€357.56B
Enterprise Value€372.14B
Total Cash (Recent Filing)$20.30B
Total Debt (Recent Filing)$35.75B
Price to Earnings (P/E)26.4
Beta0.12
Next Earnings
Jan 28, 2025EPS Estimate
€1.9Next Dividend Ex-Date
Nov 26, 2024Dividend Yield3.17%
Share Statistics
EPS (TTM)5.59
Shares Outstanding2,407,622,972
10 Day Avg. Volume2,712
30 Day Avg. Volume2,446
Standard Deviation0.05
R-Squared0.08
Alpha0.00722
Financial Highlights & Ratios
Price to Book (P/B)4.97
Price to Sales (P/S)4.20
Price to Cash Flow (P/CF)11.50
P/FCF Ratio12.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.66
Enterprise Value/Gross Profit6.35
Enterprise Value/Ebitda15.16
Forecast
1Y Price Target
€169.76Price Target Upside16.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Financial Performance And GrowthJNJ raised its 2024 adjusted operational sales growth guidance to 5.7-6.2% from 5.5-6.0%.
Pharmaceutical AdvancementsJohnson & Johnson and partner PTGX announced positive topline results from two Phase 3 trials, demonstrating significant improvement in psoriasis treatment efficacy with icotrokinra.
Strategic Growth PotentialJNJ focuses on deals that address significant unmet needs and provide technology differentiation, aligning with its strategic and financial goals.
Bears Say
Earnings GuidanceJNJ reduced its 2024 adjusted operational EPS guidance to $9.86-$9.96 from $10.00-$10.10 to account for the impact of V-Wave.
MedTech PerformanceJNJ lowered its full-year adjusted operational sales growth target for MedTech to 'closer to 5%' from 6% previously due to softness in the Asia-Pacific region, particularly in China.
Product CompetitionBiosimilars of J&J’s bestselling product Stelara are expected to be launched in the US and its sales are expected to get slashed.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.04% Insiders
18.28% Mutual Funds
14.49% Other Institutional Investors
46.65% Public Companies and
Individual Investors
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was €132.78 and its highest was €154.00 in the past 12 months.
What is Johnson & Johnson’s market cap?
Currently, no data Available
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jan 28, 2025 which is in 66 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 15, 2024. The company reported €2.283 earnings per share for the quarter, beating the consensus estimate of €2.082 by €0.201.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of €1.17 which represents an annual dividend yield of 3.17%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is €1.9.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,623,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of €2.283 in its last earnings report, beating expectations of €2.082. Following the earnings report the stock price went up 1.513%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 1B.
---
Johnson & Johnson Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€169.76 (16.58% Upside)
€169.76 (16.58% Upside)
Blogger Sentiment
Bullish
DE:JNJ Sentiment 94%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $930.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.31%
12-Months-Change
Fundamentals
Return on Equity
20.89%
Trailing 12-Months
Asset Growth
7.36%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
JNJ Company Deck
---
JNJ Earnings Call
Q3 2024
0:00 / 0:00
---
JNJ Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
€169.76
▲(16.58% Upside)
Technical Analysis
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
22/23 ratings generated profit
1 Year Average Return
+9.30%
reiterated a buy rating 6 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +9.30% per trade.
---